Back

The activity of NXL101 against community-associated methicillin-resistant Staphylococcus aureus

Abstract number: 1732_296

Morrissey I., Lowther J., Adkin R., Cooper D., Northwood J., Janes R.

Objectives: To evaluate the novel topoisomerase inhibitor NXL101 against community-associated (CA) methicillin-resistant S. aureus (MRSA).

Methods: A total of 54 CA-MRSA were investigated: 48 being recent clinical isolates from community sources within Europe and further defined as CA-MRSA by cefoxitin 30 mg disc zone of inhibition ≤19 mm, possessing staphylococcal cassette chromosome mec type IV or IVa and having full susceptibility to gentamicin (GEN). The remaining 6 were CA-MRSA reference isolates from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) collection. MIC was determined for NXL101, GEN, azithromycin (AZI), clindamycin (CLI), dalfopristin–quinupristin (D–Q), daptomycin (DAP), levofloxacin (LFX), linezolid (LZD) and vancomycin (VAN) by CLSI broth microdilution.

Results: Summary MIC data are shown in the table. NXL101 was the most active agent against CA-MRSA. A high percentage of resistance was observed to LEV and AZI, but full susceptibility was shown to most other agents apart from CLI.

 PercentageMIC (mg/L)
Suscep tibleInter mediateResistantMIN50%90%MAX 
NXL101<0.0150.060.120.5
AZI44.4055.60.25>64>64>64
CLI75.9024.10.060.12>8>8
D–Q100000.250.2512
DAP1000.120.511
GEN100000.120.250.50.5
LEV22.2077.80.12816>32
LM1000.5224
VAN100000.5111

Conclusion: NXL101 showed excellent activity against CA-MRSA, and may offer a viable alternative for the treatment of CA-MRSA and other S. aureus infections in the future.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top